Literature DB >> 833279

Secretion by glucagonomas of a possible glucagon precursor.

G C Weir, E S Horton, T T Aoki, D Slovik, J Jaspan, A H Rubenstein.   

Abstract

Five patients with glucagonomas had elevated plasma levels of total glucagon immunoreactivity. Gel filtrations of these plasma samples on Bio-Gel P30 columns showed that most of the immunoreactivity eluted in the 3,500-(true glucagon) and 9,000-dalton fractions. After the administration of alpha cell effectors, changes in total glucagon immunoreactivity were seen which were accounted for primarily by the 3,500-dalton species, but there were also changes in the 9,000-dalton moiety. Venous effluent plasma from tumors of two subjects contained elevated concentrations of glucagon immunoreactivity in both fractions. When material from both the 3,500- and 9,000-dalton peaks were serially diluted in a glucagon immunoassay, parallel displacement curves were found, suggesting that both have similar or identical antigenic determinants. Thus, with conversion to a neoplastic state, alpha cells of glucagonomas, much like beta cells of insulinomas, may secrete an increased amount of a larger, 9,000-mol wt glucagon species which may be a prohormone.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 833279      PMCID: PMC333363          DOI: 10.1172/JCI108644

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Occurrence of big renin in human plasma, amniotic fluid and kidney extracts.

Authors:  R P Day; J A Luetscher; C M Gonzales
Journal:  J Clin Endocrinol Metab       Date:  1975-06       Impact factor: 5.958

2.  Immunochemical heterogeneity of calcitonin in plasma.

Authors:  L J Deftos; B A Roos; D Bronzert; J G Parthemore
Journal:  J Clin Endocrinol Metab       Date:  1975-03       Impact factor: 5.958

3.  Glucagon radioimmunoassay using antiserum 30K: interference by plasma.

Authors:  G C Weir; R C Turner; D B Martin
Journal:  Horm Metab Res       Date:  1973-07       Impact factor: 2.936

4.  Existence of two forms of immunoreactive growth hormone in human plasma.

Authors:  A D Goodman; R Tanenbaum; D Rabinowitz
Journal:  J Clin Endocrinol Metab       Date:  1972-12       Impact factor: 5.958

5.  Evidence for "big" and "little" components of human plasma and pituitary growth hormone.

Authors:  P Gorden; C M Hendricks; J Roth
Journal:  J Clin Endocrinol Metab       Date:  1973-01       Impact factor: 5.958

6.  Size and charge distinctions between endogenous human plasma gastrin in peripheral blood and heptadecapeptide gastrins.

Authors:  R S Yalow; S A Berson
Journal:  Gastroenterology       Date:  1970-05       Impact factor: 22.682

7.  Glucagon biosynthesis in human pancreatic islets: preliminary evidence for a biosynthetic intermediate.

Authors:  B D Noe; G E Bauer; M W Steffes; D E Sutherland; J S Najarian
Journal:  Horm Metab Res       Date:  1975-07       Impact factor: 2.936

8.  Evidence of sequential metabolic cleavage of proglucagon to glucagon in glucagon biosynthesis.

Authors:  B D Noe; G E Bauer
Journal:  Endocrinology       Date:  1975-10       Impact factor: 4.736

9.  Heterogeneity of plasma glucagon: patterns in patients with chronic renal failure and diabetes.

Authors:  S F Kuku; A Zeidler; D S Emmanouel; A I Katz; A H Rubenstein
Journal:  J Clin Endocrinol Metab       Date:  1976-01       Impact factor: 5.958

10.  Studies on the biosynthesis of pancreatic glucagon in the pigeon (Columba livia).

Authors:  K J O'Connor; N R Lazarus
Journal:  Biochem J       Date:  1976-05-15       Impact factor: 3.857

View more
  9 in total

1.  Glucagonoma syndrome in a 19-year-old woman.

Authors:  M C Riddle; T A Golper; W S Fletcher; J W Ensinck; P H Smith
Journal:  West J Med       Date:  1978-07

2.  Inhibition of glucagon secretion by diphenylhydantoin in a patient with glucagonoma.

Authors:  T Machina; R Marcus; S R Levin
Journal:  West J Med       Date:  1980-04

3.  Isolation of glucagon-secreting cell lines by cloning insulinoma cells.

Authors:  R Takaki; J Ono; M Nakamura; Y Yokogawa; S Kumae; T Hiraoka; K Yamaguchi; K Hamaguchi; S Uchida
Journal:  In Vitro Cell Dev Biol       Date:  1986-03

4.  The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth.

Authors:  F Jockenhövel; S Lederbogen; T Olbricht; H Schmidt-Gayk; E P Krenning; S W Lamberts; D Reinwein
Journal:  Clin Investig       Date:  1994-01

Review 5.  Pancreatic glucagonoma with and without syndrome. Immunocytochemical study of 5 tumour cases and review of the literature.

Authors:  E Ruttman; G Klöppel; G Bommer; M Kiehn; P U Heitz
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1980

Review 6.  Multiple endocrine neoplasia syndromes.

Authors:  A Pont
Journal:  West J Med       Date:  1980-04

7.  Evidence of glucagon biosynthesis involving protein intermediates in rat salivary glands.

Authors:  A Perez Castillo; E Blazquez
Journal:  Diabetologia       Date:  1984-10       Impact factor: 10.122

8.  Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours.

Authors:  J J Holst
Journal:  Diabetologia       Date:  1983-05       Impact factor: 10.122

9.  Glucagonoma and its angiographic diagnosis.

Authors:  A S Wawrukiewicz; J Rösch; F S Keller; D A Lieberman
Journal:  Cardiovasc Intervent Radiol       Date:  1982       Impact factor: 2.740

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.